RegulatoryOfficial
UK confirms plan to widen gene therapy definition to cover synthetic and genome-editing products
🇬🇧 MHRA · Thu 19 Nov 2026
Following a consultation backed by 83% of respondents, the government will amend the Human Medicines Regulations 2012 so more synthetic and gene-editing medicines fall under the advanced therapies framework.
The UK government confirmed on 19 November 2026 that it will modernise the legal definition of gene therapy medicinal products (GTMPs). The aim is to bring certain synthetic gene therapies and novel genome-editing treatments within the established advanced therapies framework. The announcement was made at the inaugural DIA-MHRA Global Summit in London, held on 16-17 November as part of London Life Sciences Week.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.
More Regulatory
All →
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
MHRA to legislate on revised gene therapy definition after strong consultation support
🇬🇧 MHRA · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 190/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends veterinary, phytosanitary and technical regulation annexes in Decision No 194/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters in Decision 191/2026
🇪🇺 EUR-Lex · Thu 19 Nov 2026
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026